BioCryst Pharmaceuticals’ (BCRX) “Market Outperform” Rating Reiterated at JMP Securities

JMP Securities reaffirmed their market outperform rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a report issued on Friday morning,Benzinga reports. JMP Securities currently has a $18.00 price objective on the biotechnology company’s stock.

Several other research analysts have also issued reports on BCRX. Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a report on Tuesday, November 5th. Needham & Company LLC raised their price objective on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, January 13th. Finally, Barclays lifted their target price on shares of BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Stock Performance

Shares of NASDAQ:BCRX opened at $7.90 on Friday. The company’s fifty day moving average is $7.63 and its two-hundred day moving average is $7.69. BioCryst Pharmaceuticals has a 1-year low of $4.03 and a 1-year high of $8.88. The stock has a market capitalization of $1.64 billion, a price-to-earnings ratio of -12.95 and a beta of 1.76.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, November 4th. The biotechnology company reported ($0.07) EPS for the quarter, meeting the consensus estimate of ($0.07). The business had revenue of $117.10 million during the quarter, compared to analyst estimates of $113.99 million. The firm’s revenue was up 35.1% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.19) earnings per share. Sell-side analysts expect that BioCryst Pharmaceuticals will post -0.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its stake in BioCryst Pharmaceuticals by 21.5% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,483 shares of the biotechnology company’s stock worth $57,000 after buying an additional 1,322 shares during the last quarter. Captrust Financial Advisors increased its holdings in shares of BioCryst Pharmaceuticals by 19.4% during the third quarter. Captrust Financial Advisors now owns 16,274 shares of the biotechnology company’s stock valued at $124,000 after acquiring an additional 2,644 shares in the last quarter. Creative Planning raised its position in shares of BioCryst Pharmaceuticals by 5.9% during the third quarter. Creative Planning now owns 49,347 shares of the biotechnology company’s stock worth $375,000 after purchasing an additional 2,734 shares during the period. SkyView Investment Advisors LLC grew its position in BioCryst Pharmaceuticals by 30.0% in the 3rd quarter. SkyView Investment Advisors LLC now owns 13,000 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 3,000 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in BioCryst Pharmaceuticals by 7.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 51,012 shares of the biotechnology company’s stock worth $388,000 after buying an additional 3,653 shares during the last quarter. 85.88% of the stock is currently owned by institutional investors.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.